Hau R, Wright S, Cherrington N
Clin Pharmacol Ther. 2023; 114(4):780-794.
PMID: 37404197
PMC: 11347013.
DOI: 10.1002/cpt.2984.
Megias-Vericat J, Martinez-Cuadron D, Solana-Altabella A, Poveda J, Montesinos P
Pharmaceutics. 2022; 14(4).
PMID: 35456712
PMC: 9030330.
DOI: 10.3390/pharmaceutics14040878.
Daniels G
Transfus Med Hemother. 2022; 49(1):25-29.
PMID: 35221865
PMC: 8832251.
DOI: 10.1159/000520596.
Shi S, Fukuda H, Chujo T, Kouwaki T, Oshiumi H, Tomizawa K
RNA Biol. 2021; 18(sup1):478-495.
PMID: 34382915
PMC: 8677048.
DOI: 10.1080/15476286.2021.1960689.
di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G
Cancers (Basel). 2021; 13(5).
PMID: 33669053
PMC: 7956511.
DOI: 10.3390/cancers13050966.
IMPROvER: the Integral Membrane Protein Stability Selector.
Harborne S, Strauss J, Boakes J, Wright D, Henderson J, Boivineau J
Sci Rep. 2020; 10(1):15165.
PMID: 32938971
PMC: 7495477.
DOI: 10.1038/s41598-020-71744-x.
Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1).
Boswell-Casteel R, Johnson J, Hays F
Molecules. 2018; 23(4).
PMID: 29565807
PMC: 6017673.
DOI: 10.3390/molecules23040732.
Equilibrative nucleoside transporters-A review.
Boswell-Casteel R, Hays F
Nucleosides Nucleotides Nucleic Acids. 2016; 36(1):7-30.
PMID: 27759477
PMC: 5728162.
DOI: 10.1080/15257770.2016.1210805.
Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.
Daniels G, Ballif B, Helias V, Saison C, Grimsley S, Mannessier L
Blood. 2015; 125(23):3651-4.
PMID: 25896650
PMC: 4458803.
DOI: 10.1182/blood-2015-03-631598.
Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.
Pastor-Anglada M, Perez-Torras S
Front Pharmacol. 2015; 6:13.
PMID: 25713533
PMC: 4322540.
DOI: 10.3389/fphar.2015.00013.
Uptake carriers and oncology drug safety.
Sprowl J, Sparreboom A
Drug Metab Dispos. 2014; 42(4):611-22.
PMID: 24378324
PMC: 3965905.
DOI: 10.1124/dmd.113.055806.
Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.
Spratlin J, Mackey J
Cancers (Basel). 2013; 2(4):2044-54.
PMID: 24281217
PMC: 3840445.
DOI: 10.3390/cancers2042044.
Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.
Marechal R, Demols A, Van Laethem J
Drugs Aging. 2013; 30(3):155-65.
PMID: 23338795
DOI: 10.1007/s40266-013-0049-0.
ABC transporters and their role in nucleoside and nucleotide drug resistance.
Fukuda Y, Schuetz J
Biochem Pharmacol. 2012; 83(8):1073-83.
PMID: 22285911
PMC: 3319017.
DOI: 10.1016/j.bcp.2011.12.042.
Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures.
Kim J, Karpyak V, Biernacka J, Nam H, Lee M, Preuss U
PLoS One. 2011; 6(1):e16331.
PMID: 21283641
PMC: 3026043.
DOI: 10.1371/journal.pone.0016331.
Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development.
Liou G, El-Remessy A, Ibrahim A, Caldwell R, Khalifa Y, Gunes A
Curr Pharmacogenomics Person Med. 2010; 7(3):215-222.
PMID: 20953236
PMC: 2955420.
DOI: 10.2174/1875692110907030215.
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Tanaka M, Javle M, Dong X, Eng C, Abbruzzese J, Li D
Cancer. 2010; 116(22):5325-35.
PMID: 20665488
PMC: 2966859.
DOI: 10.1002/cncr.25282.
Pharmacogenomic discovery using cell-based models.
Welsh M, Mangravite L, Medina M, Tantisira K, Zhang W, Huang R
Pharmacol Rev. 2009; 61(4):413-29.
PMID: 20038569
PMC: 2802425.
DOI: 10.1124/pr.109.001461.
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Okazaki T, Javle M, Tanaka M, Abbruzzese J, Li D
Clin Cancer Res. 2009; 16(1):320-9.
PMID: 20028759
PMC: 2802655.
DOI: 10.1158/1078-0432.CCR-09-1555.
Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Candelaria M, De la Cruz-Hernandez E, Perez-Cardenas E, Trejo-Becerril C, Gutierrez-Hernandez O, Duenas-Gonzalez A
Med Oncol. 2009; 27(4):1133-43.
PMID: 19902390
DOI: 10.1007/s12032-009-9349-y.